Recurrent Respiratory Papillomatosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports
The latest healthcare forecast report provides an in-depth analysis of Recurrent Respiratory Papillomatosis, offering comprehensive insights into the Recurrent Respiratory Papillomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Recurrent Respiratory Papillomatosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Recurrent Respiratory Papillomatosis therapies. Additionally, we cover the landscape of Recurrent Respiratory Papillomatosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Recurrent Respiratory Papillomatosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Recurrent Respiratory Papillomatosis space.
Some of the key facts of the Recurrent Respiratory Papillomatosis Market Report:
The Recurrent Respiratory Papillomatosis market size was valued ~USD 10.26 million in 2023 and is anticipated to grow with a significant CAGR of 39.9% during the study period (2020-2034)
In February 2025, INOVIO (NASDAQ: INO), a biotechnology company focused on developing DNA medicines for HPV-related conditions, cancer, and infectious diseases, announced that peer-reviewed results from its Phase 1/2 trial of INO-3107 for recurrent respiratory papillomatosis (RRP) have been published in Nature Communications. The study, titled DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107, revealed that INO-3107 stimulated new T cell populations in the blood that migrated to the airway and papilloma tissues, correlating with fewer surgeries post-treatment. Of the 32 patients enrolled, 26 (81%) needed fewer surgical interventions after treatment compared to the year before. The therapy was also well tolerated. INOVIO intends to submit a Biologics License Application (BLA) for INO-3107 by mid-2025 and will seek rolling submission and priority review through the FDA's accelerated approval pathway. If approved, INO-3107 would become the first DNA-based medicine approved for any condition in the U.S.
In December 2024, Precigen, Inc. announced that it has completed the submission of its biologics license application (BLA) to the FDA for PRGN-2012 (zopapogene imadenovec†) as a treatment for adult recurrent respiratory papillomatosis (RRP).
In August 2024, Precigen announced a strategic shift to concentrate on the potential commercialization of PRGN-2012. As part of this realignment, the company will reduce its workforce by 20% and halt all preclinical programs. This decision highlights Precigen's dedication to advancing PRGN-2012 and reallocating resources to enhance its commercial potential.
The EU4 and the UK represented about 16% of the 7MM market size, with the RRP market valued at approximately USD 1.66 million in 2023.
In 2023, Germany had the largest market size for RRP among the EU countries, reaching nearly USD 0.45 million, whereas Spain had the smallest market size, approximately USD 0.25 million.
The overall market size of RRP is expected to increase during the forecast period, driven by the anticipated introduction of emerging therapies such as INO-3107, PRGN-2012, and others.
Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others
Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others
The Recurrent Respiratory Papillomatosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Recurrent Respiratory Papillomatosis pipeline products will significantly revolutionize the Recurrent Respiratory Papillomatosis market dynamics.
The total number of diagnosed prevalent cases of RRP in the US was approximately 16,980 in 2023 and is expected to rise during the forecast period.
According to DelveInsight's estimates, the US has the highest number of diagnosed prevalent cases of RRP among the 7MM, followed by the EU4 and the UK, with Japan contributing to 24% and 10% of all RRP cases, respectively.
In 2023, Japan reported the highest number of RRP cases in adults aged 18 and older (~2,400), followed by adolescents aged 9-17 years (~50). The fewest cases were observed in children aged 0-8 years, with a total of approximately 25.
In 2023, the EU4 and the UK reported a total of approximately 6,240 diagnosed prevalent cases of RRP, with around 5,740 cases linked to HPV 6 and/or HPV 11, and about 500 cases associated with other high-risk subtypes such as HPV-16, 18, 31, 33, and 39. The large number of cases related to HPV 6 and 11 highlights the dominant role these strains play in RRP, as they are the primary causative agents.
In 2023, Germany reported the highest number of diagnosed prevalent RRP cases among the EU4 and the UK, with nearly 1,684 cases. France followed with around 1,370 cases, Italy had approximately 1,220, the UK reported about 1,022, and Spain had the lowest with roughly 944 cases. This distribution underscores the differing disease burden across European countries.
Recurrent Respiratory Papillomatosis Overview
Recurrent Respiratory Papillomatosis (RRP) is a rare condition characterized by the growth of benign tumors, called papillomas, in the airways, primarily affecting the larynx, trachea, and bronchi. These growths are caused by infection with the human papillomavirus (HPV), particularly types 6 and 11. RRP can lead to airway obstruction, hoarseness, breathing difficulties, and recurrent infections. The condition is chronic, often requiring repeated surgical interventions to remove the papillomas. It can occur in both children (juvenile-onset RRP) and adults (adult-onset RRP), with varying severity and progression.
Recurrent Respiratory Papillomatosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Recurrent Respiratory Papillomatosis Epidemiology Segmentation:
The Recurrent Respiratory Papillomatosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Recurrent Respiratory Papillomatosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Recurrent Respiratory Papillomatosis market or expected to get launched during the study period. The analysis covers Recurrent Respiratory Papillomatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Recurrent Respiratory Papillomatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Recurrent Respiratory Papillomatosis Market Drivers
Increasing Incidence of HPV Infections
Advancements in Surgical and Therapeutic Options
Rising Awareness and Early Diagnosis
Improved Treatment Modalities
Research and Development Investments
Recurrent Respiratory Papillomatosis Market Barriers
Limited Awareness and Diagnosis
Lack of Cure
High Treatment Costs
Fragmented Treatment Landscape
Limited Availability of Effective Therapies
Challenges in HPV Vaccination Implementation
Scope of the Recurrent Respiratory Papillomatosis Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others
Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others
Recurrent Respiratory Papillomatosis Therapeutic Assessment: Recurrent Respiratory Papillomatosis current marketed and Recurrent Respiratory Papillomatosis emerging therapies
Recurrent Respiratory Papillomatosis Market Dynamics: Recurrent Respiratory Papillomatosis market drivers and Recurrent Respiratory Papillomatosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Recurrent Respiratory Papillomatosis Unmet Needs, KOL's views, Analyst's views, Recurrent Respiratory Papillomatosis Market Access and Reimbursement
Table of Contents
1. Recurrent Respiratory Papillomatosis Market Report Introduction
2. Executive Summary for Recurrent Respiratory Papillomatosis
3. SWOT analysis of Recurrent Respiratory Papillomatosis
4. Recurrent Respiratory Papillomatosis Patient Share (%) Overview at a Glance
5. Recurrent Respiratory Papillomatosis Market Overview at a Glance
6. Recurrent Respiratory Papillomatosis Disease Background and Overview
7. Recurrent Respiratory Papillomatosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Recurrent Respiratory Papillomatosis
9. Recurrent Respiratory Papillomatosis Current Treatment and Medical Practices
10. Recurrent Respiratory Papillomatosis Unmet Needs
11. Recurrent Respiratory Papillomatosis Emerging Therapies
12. Recurrent Respiratory Papillomatosis Market Outlook
13. Country-Wise Recurrent Respiratory Papillomatosis Market Analysis (2020–2034)
14. Recurrent Respiratory Papillomatosis Market Access and Reimbursement of Therapies
15. Recurrent Respiratory Papillomatosis Market Drivers
16. Recurrent Respiratory Papillomatosis Market Barriers
17. Recurrent Respiratory Papillomatosis Appendix
18. Recurrent Respiratory Papillomatosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
44 minutes ago
- CTV News
UnitedHealth says it is under a U.S. federal investigation and co-operating
The logo for UnitedHealth Group appears above a trading post on the floor of the New York Stock Exchange, April 17, 2025. (AP Photo/Richard Drew) Shares of UnitedHealth Group slipped Thursday after the health care giant said it was under a U.S. Department of Justice investigation. The company said it has started complying with both criminal and civil requests from federal investigators and it was cooperating with them. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper then said earlier this month that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth Group Inc. said that it reached out to the Justice Department 'after reviewing media reports about investigations into certain aspects of the company's participation in the Medicare program.' UnitedHealth runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than US$400 billion in revenue last year as the third-largest company in the Fortune 500. Last year, its share price topped $630 to reach a new all-time high. But company shares have mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A 26-year-old suspect, Luigi Mangione, has been charged in connection with the shooting. In April, shares plunged after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned and the company withdrew its forecast. The stock price slipped another 2%, or $5.12, to $287.39 Thursday morning. That represents a 54% drop from its all-time high. UnitedHealth will report its second-quarter results next Tuesday. Tom Murphy, The Associated Press
CTV News
44 minutes ago
- CTV News
Sask. adding 77 permanent positions to rural hospitals
WATCH: As Wayne Mantyka tells us, help is on the way for those working in rural hospitals across Saskatchewan. The province says help is on the way for rural hospitals across Saskatchewan, with 77 full-time positions being created across 30 communities. The province hopes it will help stabilize the provision of emergency and other services. 'I am pleased that we have the chance to celebrate the ongoing efforts to reduce service disruptions in rural and northern communities and today I am very pleased to announce 77 new and enhanced permanent full-time positions to 30 different rural and northern communities,' Health Minister Jeremy Cockrill said on Wednesday. Most of the 77 positions are currently being filled by part-time and temporary staff, but it's difficult to retain workers without offering full-time job stability. 'Adding more full-time roles will help attract more professionals, support existing employees by providing better staffing coverage, improve team cohesiveness and provide a safer work environment for workers and providers,' Cockrill said. Cockrill made the announcement in Moose Jaw, where seven permanent nursing jobs will be added. Other rural communities like Kipling, southeast of Regina, will gain two permanent nursing positions. The Opposition NDP is questioning how the positions will be filled. 'You know as of this morning according to publicly available data, we have 1,647 vacant health care positions in the province and so why should people believe that [with] these 77 the Sask. Party will be able to fill whereas the previous 1,647 they could not,' NDP MLA Keith Jorgenson said. The Saskatchewan Health Authority does not know how long it will take to fill the 77 permanent positions but with any of the spots already filled by parttime and temporary workers, convincing them to go full-time could make the job easier.
CTV News
an hour ago
- CTV News
Montreal-area nurse and mother of 3 says high cost of a service dog is holding her back
A Montreal-area nurse who has Ehlers–Danlos syndrome needs a service dog but has to pay $35,000 to get one. For Josee St-Onge, tasks as simple as preparing a meal can become a painful endeavour because she suffers from a disease called Ehlers–Danlos syndrome, a form of hypermobility disorder. 'Most people think of hypermobility as just a joint instability issue,' explained the mother of three. 'But in fact it encompasses so much more. So a lot of us are affected neurologically, with our digestion, skin issues, difficulty managing our blood pressure, our temperature. And of course, the biggest issue is damage from all the instability in the joints over time.' Something as simple as opening a door or bumping into someone can lead to joints dislocating. 'I don't have any ligaments supporting my wrist and most of my fingers are very, very mobile, so they tend to pop out very easily.' St-Onge, who is a registered nurse, works part-time from home, interacting with patients. But what she says she needs the most is a service dog that could help her with her mobility. 'The first thing is to really minimize the impact of my day-to-day on my hands and try to preserve as much mobility and strength as possible,' explains St-Onge. 'So she'll be helping me. You know, open doors, open my stove, my fridge. So she's trained to be able to go get my phone, go get me water, retrieve dropped items.' Quebec's two agencies that provide service dogs are overwhelmed with the demand from people with physical or mental conditions. The normal wait time would be at least two years. But right now, they're not even accepting new applications. 'You know, it breaks our heart to receive all these calls, to receive all these emails and that we just can't help. We feel helpless at times,' said John Agionicolaitis from the Asista foundation, which provides dogs for people suffering from PTSD, anxiety and other mental-health issues. The cost is also prohibitive without the backing of a charity. The MIRA Foundation tries to provide service dogs at no cost to those in need. But the financing isn't large enough to provide a dog to everyone who needs it. 'We calculate our dogs in the average of all of our programs. So we estimate it at, like, $35,000, but I think now we should say more. So it's really, really expensive,' explained Aurelie Tremblay from the MIRA Foundation. St-Onge did find help at the Summit Assistance Dogs Center in Medicine Hat, Alberta. But she can't afford the $35,000 investment. Despite having a job, she had to turn to the public for help. 'I'm very disappointed in the lack of access for me, especially for people with invisible disabilities. It's so hard to access any type of support or funding from the government. And the reality is our expenses are so much higher than the average person, you know, because each month we have specific medications or mobility aids or we have to take more time off work to go see a specialist.' With the help of the community in Ste-Anne-de-Bellevue, she has managed to raise half the amount needed, which includes the trip to Alberta's training centre. 'Over the past six months, we've held music events, we've held trivia nights online, raffles, we've had the GoFundMe link that's been live. We've been really working hard to try to get my story out there. And that's what's brought us almost $18,000 so far.' And if St-Onge can come up with the balance, she says she'll be able to once again have a resemblance to a normal life.
